Ovarian Cancer

Results of a phase I expansion study demonstrated a manageable safety profile and clinical activity with mirvetuximab soravtansine in the treatment of patients with platinum-resistant ovarian cancer.

Douglas A. Levine, MD, discussed the relationship between EMSY and BRCA, the potential to target EMSY amplified tumors with PARP inhibitors, and the future of ovarian cancer treatment.

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses some of the ongoing challenges researchers need to tackle in the field of ovarian cancer.

Mansoor Raza Mirza, MD, chief oncologist at Rigshospitalet, Copenhagen, Denmark, discusses the efficacy of niraparib as a treatment of patients with ovarian cancer.

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses what potential PARP inhibitors could have with chemotherapy regimens as a treatment for patients with ovarian cancer.

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses the GOG 252 trial, which looked at the use of intravenous versus intraperitoneal chemotherapy in the treatment of patients with ovarian cancer.

Diagnostic laparoscopy reduced the number of futile laparotomies in patients with suspected advanced-stage ovarian cancer, according to the results of a recent study.

Long or irregular menstrual cycles may be a marker of an increased risk for developing certain subtypes of ovarian cancer, according to the results of a recent study.

Franco M. Muggia, MD, discusses the results of the Gynecologic Oncology Group (GOG) 252 trial and what the findings mean regarding intraperitoneal therapy for patients with ovarian cancer.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses combination treatments in ovarian cancer.